Overview
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to <18 years of age with moderate-to-severe atopic dermatitis (AD).
Eligibility
Inclusion Criteria:
- Have a diagnosis of AD prior to screening as stated in the criteria by the American
Academy of Dermatology for at least:
- 12 months s if participants are ≥6 years of age, and
- 6 months if participants are 6 months to <6 years of age
- Have an EASI score ≥16 at the screening and baseline
- Have an IGA score ≥3 (scale of 0 to 4) at the screening and baseline
- Have ≥10% BSA of AD involvement at the screening and baseline.
Exclusion Criteria:
- Are currently enrolled or have participated within the last 8 weeks in a clinical study involving an investigational intervention or any other type of medical research judged not to be scientifically or medically compatible with this study.
- Treatment with the following prior to the baseline:
- An investigational drug within 8 weeks or less than 5 half-lives, whichever is longer.
- Dupilumab within 8 weeks. Note: The enrollment of participants with prior use of Dupilumab will be limited to <20%.
- Treatment with a topical investigational drug within 2 weeks prior to the baseline.
- Have received a Bacillus Calmette-Guerin vaccination or treatment within less than 4 weeks before randomization.